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What is the problem and what is known about it so far?
Type 2 diabetes mellitus interferes with the body's ability to store energy from food, resulting in high levels of blood sugar that can lead to such problems as kidney failure, blindness, and heart disease. Insulin helps the body convert food to stored energy and keeps blood sugar levels within the normal range. In type 2 diabetes, body tissues are resistant to the effects of insulin and blood sugar levels are high. Some patients can overcome these abnormalities with diet and exercise alone. However, many patients need to add drug treatment to control blood sugar levels. Drugs include insulin (an injectable drug) and a variety of oral drugs. People who inject insulin need to check their blood sugar levels throughout the day to make sure that they are getting the right amount of insulin and that their levels are not too high or too low. This can be done by taking a small sample of blood from a finger pinprick and checking it with an instrument called a glucometer. Another way to check blood sugar levels is continuous glucose monitoring (CGM). Continuous glucose monitoring involves a small tube placed under the skin (usually in the abdomen) and an instrument that continuously checks blood sugar levels throughout the day. Continuous glucose monitoring has been shown to be helpful in people with type 1 diabetes who must take insulin to survive. However, it is not known if CGM is better for people with type 2 diabetes than usual care, which is checking with a regular glucometer several times per day.
Why did the researchers do this particular study?
To compare CGM with usual care glucose monitoring (checking glucose several times each day) in people with type 2 diabetes who were taking insulin.
Who was studied?
158 adults with type 2 diabetes who were 35 to 79 years old and taking multiple daily injections of insulin.
How was the study done?
The researchers randomly assigned patients to use CGM or to continue checking blood sugar the way they previously had been. They followed patients for 6 months and measured hemoglobin A 1c (HbA 1c ) levels. The HbA 1c blood test indicates the level of blood sugar control over the prior 3 months.
What did the researchers find?
After 6 months, HbA 1c levels decreased more in the CGM group than in the usual care group. There were no differences between the groups in quality of life or in episodes of dangerously low blood sugar (hypoglycemia).
What were the limitations of the study?
The study was only 6 months long. Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
